Frazier Life Sciences Appoints Charles Fuchs as Senior Advisor

PALO ALTO, Calif.--(BUSINESS WIRE)--Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Charles (Charlie) Fuchs, M.D., M.P.H., as Senior Advisor.

Dr. Fuchs brings extensive experience as an innovator and executive leader spanning oncology, immunology, and translational medicine, with a proven track record of advancing programs through global product development and regulatory approvals. Most recently, Dr. Fuchs served as Senior Vice President and Global Head of Product Development for Oncology and Hematology at Roche, where he led the development and execution of a new, comprehensive global strategy for Roche’s Oncology and Hematology division. In this role, Dr. Fuchs drove portfolio growth, oversaw the approval of multiple new therapies and indications across cancer and blood disorders, and led the strategic acquisition of external assets to strengthen the division’s portfolio.

“Dr. Fuchs brings a depth of experience across oncology, immunology and global drug development, which will be an invaluable asset as we continue to partner with companies building transformative medicines,” said Jamie Topper, Managing Partner at FLS. “We are pleased to welcome him to the Frazier team.”

Prior to his work with Genentech and Roche, Dr. Fuchs served as the Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital, where he managed a highly integrated, state-of-the-art clinical and research operation spanning 16 facilities across New England. Additionally, during his tenure, he played a key role in launching several biotech start-ups rooted in Yale science.

Dr. Fuchs has also served on advisory boards for numerous cancer centers, foundations, biotechnology companies and pharmaceutical organizations, and co‑founded EvolveImmune Therapeutics. Earlier in his academic career, he was Professor of Medicine at Harvard Medical School and served as Chief of the Gastrointestinal Oncology Division at Dana-Farber Cancer Institute and the Robert T. and Judith B. Hale Chair in Pancreatic Cancer.

“The Frazier Life Sciences team has demonstrated a long, successful history of supporting companies at critical moments in their evolution,” said Dr. Fuchs. “I look forward to guiding the entrepreneurs who are seeking to translate cutting edge biology into meaningful therapies for patients.”

Dr. Fuchs received his M.D. and M.P.H. from Harvard University and holds a B.A. in Biochemistry from the University of Pennsylvania. He completed post-graduate training in Internal Medicine, Medical Oncology, and Hematology at Brigham and Women’s Hospital and Dana-Farber Cancer Institute in Boston.

About Frazier Life Sciences:

Frazier Life Sciences (FLS) invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. Since 2016, the firm has raised over $5.3 billion including venture funds focusing on company creation and private companies and long-only public funds focused on small and mid-cap public companies. Since 2010, FLS portfolio companies have achieved 76 FDA-approved therapeutics and completed more than 60 IPOs or strategic acquisitions.

FLS is headquartered in Palo Alto, CA, with offices in San Diego, Seattle and Boston.

For more information about FLS, please visit frazierls.com and follow us on LinkedIn.